Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779719 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1HPGDLMNATHRB | |
| SCHEMBL3780649 | 0.92 | PPARG (0.45) | KDM4EALDH1A1HPGDLMNATHRB | |
| SCHEMBL3405061 | 0.92 | PPARG (0.45) | KDM4EALDH1A1HPGDLMNATHRB | |
| SCHEMBL603590 | 0.78 | PIK3CA (0.46) | KDM4EALDH1A1 | |
| SCHEMBL603591 | 0.78 | PIK3CA (0.46) | KDM4EALDH1A1 | |
| SCHEMBL15850919 | 0.75 | KCNA5 (0.43) | KDM4EALDH1A1HSD17B10MTNR1AMTNR1B | |
| SCHEMBL10285563 | 0.73 | KCNH2 (0.58) | — | |
| SCHEMBL15850921 | 0.72 | HTR1A (0.41) | KDM4EALDH1A1HSD17B10MTNR1AMTNR1B | |
| SCHEMBL12065370 | 0.71 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL23963101 | 0.71 | PPARG (0.44) | ALDH1A1LMNAPPARGPPARAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254887-B9 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8349826-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2254887-B1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2254887-A1 | OXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | OXA1L, UQCRB, O60361 | KDM4E 2765/4885ALDH1A1 367/4885HPGD 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.